secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0000078003-25-000159
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh
--------------------------------------------------------------------------------

- Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.
- Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.
- Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).
- Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/0000078003-25-000159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer